Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 11th Nov 2013 08:50

Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p.Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation.British Land: Deutsche Bank downgrades to sell with a target price of 520p.British Sky Broadcasting: Nomura reduces target price from 1040p to 850p and downgrades from buy to reduce. Goldman Sachs cuts target price from 1120p to 1070p, while reiterating its buy recommendation.BT Group: JP Morgan increases target price from 380p to 420p upgrading from neutral to overweight. Citi ups target price from 400p to 430p retaining a buy recommendation. UBS cuts target price from 310p to 290p and stays with its sell recommendation.Cable & Wireless Communications: Jefferies shifts target price from 45p to 48p and retains a hold recommendation.Carr's Milling: Investec places both its target price (prev.: 1710p) and its buy recommendation under review.Cobham: Investec cuts target price from 275p to 230p retaining its sell recommendation.Dignity: Investec raises target price from 1562p to 1583p and upgrades from add to buy.Faroe Petroleum: Panmure Gordon moves target price from 182p to 188p and retains a buy recommendation. Westhouse Securities shifts target price from 175p to 185p and maintains a buy recommendation.FlyBe: Liberum Capital initiates with a target price of 90p and a buy recommendation.Gemfields: Investec moves target price from 30p to 37.5p and reiterates a buy recommendation.International Consolidated Airlines Group: Citi raises target price from 380p to 535p and stays with its buy recommendation. HSBC takes target price from 405p to 420p maintaining an overweight rating. Credit Suisse increases target price from 345p to 443p and reiterates an outperform rating.International Personal Finance: RBC Capital shifts target price from 700p to 695p and maintains an outperform rating.ITV: Citi ups target price from 180p to 191p, while downgrading from buy to neutral. Goldman Sachs lowers target price from 240p to 237p and retains a buy recommendation.Lonmin: Investec places its target price (prev.: 266p), while leaving its sell recommendation unaltered.Morgan Advanced Materials: Investec places its target price (prev.: 410p) under review, while keeping its buy recommendation.Paragon Group: RBC Capital ups target price from 350p to 390p upgrading to outperform.Rentokil Initial: JP Morgan moves target price from 75p to 86p, while leaving its underweight rating unchanged.Royal Bank of Scotland: Jefferies raises target price from 390p to 441p and keeps a buy recommendation.RSA Insurance Group: Citi reduces target price from 146p to 126p downgrading from buy to neutral. Panmure Gordon moves target price from 98p to 117p, but still recommends selling. Credit Suisse lowers target price from 125p to 110p and downgrades to underperform.Shire: Panmure Gordon raises target price from 2850p to 3100p and keeps a buy recommendation.Tullett Prebon: UBS cuts target price from 315p to 290p and maintains its sell recommendation.Verona Pharma: N+1 Singer initiates with a target price of 5.1p and a buy recommendation.Wincanton: Investec ups target price from 75p to 122p, while downgrading from buy to hold.
More News
13 Jan 2020 11:08

Verona Pharma shares surge after results from latest study

(Sharecast News) - Respiratory disease-focussed biopharmaceuticals company Verona Pharma announced positive top-line data from a four week, 416 patient phase 2b dose-ranging study evaluating nebulised ensifentrine or placebo as an add-on treatment to 'Spiriva Respimat', or tiotropium, which is a long acting anti-muscarinic bronchodilator, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

Read more
13 Jan 2020 10:34

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

Read more
13 Jan 2020 07:56

Verona Pharma Says Ensifentrine Study Shows Positive Results

Verona Pharma Says Ensifentrine Study Shows Positive Results

Read more
5 Nov 2019 11:29

Verona Pharma losses widen as it pours resources into ensifentrine

(Sharecast News) - Biopharmaceutical company Verona Pharma updated the market on its operations and finances for the three and nine months ended 30 September on Tuesday, highlighting positive results from the second part of its phase 2 study of the dry powder inhaler formulation of 'ensifentrine' in chronic obstructive pulmonary disorder (COPD), delivered by handheld inhaler over one week of twice-daily treatment.

Read more
5 Nov 2019 10:38

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

Read more
5 Nov 2019 10:15

Verona Pharma Third Quarter Loss Widens On Research & Development

Verona Pharma Third Quarter Loss Widens On Research & Development

Read more
29 Oct 2019 15:30

Inland Homes snaps up 50% stake in Cheshunt Lakeside Development

(Sharecast News) - Inland Homes on Tuesday acquired a 50% interest in joint-venture partner Cheshunt Lakeside Developments Limited that was held by CPC Group Limited.

Read more
6 Aug 2019 12:01

Verona Pharma Loss Widens In First Half On Clinical Trial Expenses

(Alliance News) - Verona Pharma PLC on Tuesday said its loss widened in the second quarter and the first half of 2019 as it progressed on clinical trials of Ensifentrine, used for the treatment of

Read more
5 Aug 2019 10:42

WINNERS & LOSERS SUMMARY: Risk-Off Trade Sends Gold Miners Higher

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 3.1%. The Mexican gold miner rose as the price of

Read more
5 Aug 2019 09:44

Verona Pharma Shares Jump 15% On Positive Ensifentrine Study Results

(Alliance News) - Verona Pharma PLC on Monday reported positive second phase test data for a dry powder inhaler formulation of its lead development product ensifentrine.The stock was 15% in

Read more
25 Jun 2019 15:31

Verona Pharma strengthens clinical team ahead of next round of trials

(Sharecast News) - Respiratory-focussed biopharmaceutical company Verona Pharma announced two senior appointments to its clinical team on Tuesday.

Read more
29 May 2019 16:23

Director dealings: Piers Morgan's spouse ups stake in Verona Pharma

(Sharecast News) - Verona Pharma revealed on Wednesday that chief financial officer Piers Morgan's wife Kayt Morgan had acquired 33,802 ordinary shares in the AIM-listed biotechnology outfit.

Read more
7 May 2019 14:41

Verona Pharma announces next study of nebulised ensifentrine

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a phase 2b dose-ranging study evaluating nebulised ensifentrine (RPL554) added on to a long-acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) on Tuesday.

Read more
9 Apr 2019 15:25

Verona Pharma Gets EU Patent For COPD Clinical Candidate Ensifentrine

LONDON (Alliance News) - Verona Pharma PLC on Tuesday said it secured a key patent from the European Patent Office relating to its lead development candidate, ensifentrine.The clinical that

Read more
9 Apr 2019 08:23

Verona Pharma gets another European patent on ensifentrine

(Sharecast News) - Respiratory disease-focussed clinical stage biopharmaceutical company Verona Pharma announced on Tuesday that the European Patent Office had granted an additional key patent relating to its lead development candidate, 'ensifentrine'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.